Equities
Health CarePharmaceuticals & Biotechnology
  • Price (CHF)335.60
  • Today's Change-0.80 / -0.24%
  • Shares traded282.45k
  • 1 Year change9.07%
  • Beta1.1319
Data delayed at least 15 minutes, as of Dec 13 2019 16:30 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life science industries. The Company's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The Company divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.

  • Revenue in CHF (TTM)5.44bn
  • Net income in CHF644.00m
  • Incorporated2002
  • Employees14.70k
  • Location
    Lonza Group AGMuenchensteinerstrasse 38BASEL 4052SwitzerlandCHE
  • Phone+41 613168111
  • Fax+41 613169111
  • Websitehttps://www.lonza.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
LONN:VTX since
announced
Transaction
value
Novartis AG-Fill & Finish Facility SteinAnnounced01 Jul 201901 Jul 2019Announced1.88%--
Data delayed at least 15 minutes, as of Dec 13 2019 16:30 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Galapagos NV946.82m306.72m13.31bn918.0042.684.6041.8714.054.414.4115.9540.920.2358--29.861,193,418.007.64-6.258.71-7.32----32.39-31.79--2.920.0097--103.8526.9074.71--11.74--
Genmab A/S533.05m223.73m14.00bn533.0061.967.61--26.2623.7123.7157.32193.050.3512--4.149,656,817.0014.7420.3615.4722.75----41.9752.53----0.01490.0027.8935.4533.4083.81115.11--
UCB SA5.13bn713.49m15.27bn7.50k20.662.0814.252.983.473.5224.9334.420.45251.835.20625,216.806.555.008.316.4973.9071.7014.4712.520.887110.100.17744.362.258.135.3257.39-0.1751.66
Grifols SA5.43bn603.78m20.46bn22.28k39.074.4823.883.770.79960.79967.226.980.38431.2910.70233,516.304.455.805.046.5345.3748.3711.5813.890.95543.300.580421.143.9110.35-9.9711.5412.2311.49
Lonza Group AG5.44bn644.00m24.99bn14.70k38.864.02--4.598.646.1072.9483.410.3956----353,756.104.714.925.766.1737.6934.4611.909.88--12.220.377338.8221.869.11-1.3649.7422.206.67
Data as of Dec 13 2019. Currency figures normalised to Lonza Group AG's reporting currency: Swiss Franc CHF

Institutional shareholders

20.93%Per cent of shares held by top holders
HolderShares% Held
BlackRock Investment Management (UK) Ltd.as of 30 Nov 20192.26m3.04%
Artisan Partners LPas of 31 Dec 20182.25m3.02%
The Vanguard Group, Inc.as of 31 Oct 20192.08m2.79%
Fidelity Management & Research Co.as of 31 Oct 20191.76m2.36%
Norges Bank Investment Managementas of 31 Dec 20181.60m2.15%
TIAA-CREF Investment Management LLCas of 30 Sep 20191.27m1.71%
UBS Asset Management Switzerland AGas of 04 Dec 20191.20m1.61%
Invesco Advisers, Inc.as of 30 Sep 20191.09m1.47%
Harding Loevner LPas of 31 Oct 20191.08m1.45%
BlackRock Fund Advisorsas of 05 Dec 20191.00m1.34%
More ▼
Data from 31 Dec 2018 - 10 Dec 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.